Lineage Cell Therapeutics' OpRegen is partnered with Genentech/Roche. In my view, this is their main value driver in GA dry AMD. Looking ahead, their GAlette Phase 2a trial is enrolling, which could further validate the rest of their portfolio's potential. LCTX's pipeline also has OPC1 for spinal cord injury. Its preclinical R&D includes ANP1, PNC1, RND1, and ILT1.
Lineage, Inc. ( LINE ) Q3 2025 Earnings Call November 5, 2025 8:00 AM EST Company Participants Ki Bin Kim W. Lehmkuhl - CEO, President & Director Robert Crisci - Chief Financial Officer Conference Call Participants Caitlin Burrows - Goldman Sachs Group, Inc., Research Division Michael Goldsmith - UBS Investment Bank, Research Division Steve Sakwa - Evercore ISI Institutional Equities, Research Division Craig Mailman - Citigroup Inc., Research Division Ronald Kamdem - Morgan Stanley, Research Division Michael Carroll - RBC Capital Markets, Research Division Alexander Goldfarb - Piper Sandler & Co., Research Division Omotayo Okusanya - Deutsche Bank AG, Research Division Greg McGinniss - Scotiabank Global Banking and Markets, Research Division Daniel Guglielmo - Capital One Securities, Inc., Research Division Vikram Malhotra - Mizuho Securities USA LLC, Research Division Blaine Heck - Wells Fargo Securities, LLC, Research Division Michael Lewis Samir Khanal - BofA Securities, Research Division Michael Mueller - JPMorgan Chase & Co, Research Division Todd Thomas - KeyBanc Capital Markets Inc., Research Division Nicholas Thillman - Robert W.
The headline numbers for Lineage, Inc. (LINE) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
| Industrial REITs Industry | Real Estate Sector | W. Gregory Lehmkuhl CEO | NASDAQ (NGS) Exchange | 53566V106 CUSIP |
| US Country | 26,000 Employees | 30 Sep 2025 Last Dividend | - Last Split | - IPO Date |
Lineage, Inc., a subsidiary of BG Lineage Holdings, LLC, stands as the largest global warehouse real estate investment trust (REIT) specializing in temperature-controlled spaces. Our real estate portfolio, as of March 31, 2024, boasts over 84.1 million square feet (3.0 billion cubic feet of capacity) across 482 warehouses. These strategically located properties span across critical distribution markets with 312 in North America, 82 in Europe, and 88 in Asia-Pacific. Our client base is expansive and diverse, including over 13,000 customers ranging from the biggest names in food retailing, manufacturing, processing, and distribution. Financial performance for the quarter ending March 31, 2024, revealed $1.3 billion in revenue and a net loss of $48.0 million. For the fiscal year 2023, the company achieved $5.3 billion in revenue, with a net loss of $96.2 million. These figures underscore our firm's pivotal role in the global temperature-controlled supply chain, offering unparalleled and technologically advanced solutions to a myriad of customer requirements.
Our portfolio of products and services is designed to meet the diverse and intricate needs of the temperature-controlled supply chain. Each offering is underpinned by our vast global network and cutting-edge technology, ensuring seamless and efficient logistics solutions.